TVGNW TEVOGEN BIO HLDGS INC revenue, earnings and financials
For the quarter ended June 30, 2026, TEVOGEN BIO HLDGS INC reported revenue of n/a, net income of −$5.76M and diluted EPS of −$1.52; for the fiscal year ended December 2025 revenue was n/a.
TVGNW annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$26.1M, net income −$26.3M (margin n/a), EPS −$8.08
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$53.6M, net income −$13.7M (margin n/a), EPS −$3.50
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$8.84M, net income −$60.5M (margin n/a), EPS −$2.44
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income n/a, net income $4.41M (margin n/a), EPS n/a
TVGNW quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$5.76M, EPS −$1.52
- Quarter ended Mar 31, 2026: revenue n/a, net income −$5.45M, EPS −$1.61
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$4.68M, EPS −$3.09
- Quarter ended Sep 30, 2025: revenue n/a, net income −$5.73M, EPS −$0.03
- Quarter ended Jun 30, 2025: revenue n/a, net income −$5.50M, EPS −$1.71
- Quarter ended Mar 31, 2025: revenue n/a, net income −$10.4M, EPS −$3.25
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$9.44M, EPS −$3.17
- Quarter ended Sep 30, 2024: revenue n/a, net income −$5.88M, EPS −$0.03
- Quarter ended Jun 30, 2024: revenue n/a, net income −$9.66M, EPS −$0.04
- Quarter ended Mar 31, 2024: revenue n/a, net income $11.3M, EPS −$0.26
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$3.63M, EPS −$1.97
- Quarter ended Sep 30, 2023: revenue n/a, net income −$3.90M, EPS −$0.03
- Quarter ended Jun 30, 2023: revenue n/a, net income −$22.2M, EPS −$0.18
- Quarter ended Mar 31, 2023: revenue n/a, net income −$30.8M, EPS −$0.26
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income $2.61M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income $1.61M, EPS n/a
- Quarter ended Jun 30, 2022: revenue n/a, net income $207K, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$26.0K, EPS $0.00
- Quarter ended Sep 30, 2021: revenue n/a, net income −$115, EPS n/a
- Quarter ended Jun 30, 2021: revenue n/a, net income −$11.3K, EPS n/a
TVGNW cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$12.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$12.0M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$8.17M, share buybacks $343M
- Fiscal year ended Dec 2022: operating cash flow −$215K, share buybacks n/a
TVGNW balance sheet
- Jun 30, 2026: cash n/a, total assets $4.73M, total liabilities $13.6M, shareholders' equity −$8.89M
- Mar 31, 2026: cash n/a, total assets $4.92M, total liabilities $14.8M, shareholders' equity −$9.84M
- Dec 31, 2025: cash $0, total assets $4.38M, total liabilities $12.6M, shareholders' equity −$8.23M
- Sep 30, 2025: cash n/a, total assets $4.49M, total liabilities $12.3M, shareholders' equity −$7.82M
- Jun 30, 2025: cash n/a, total assets $4.27M, total liabilities $13.8M, shareholders' equity −$9.48M
- Mar 31, 2025: cash n/a, total assets $4.07M, total liabilities $11.8M, shareholders' equity −$7.72M
- Dec 31, 2024: cash $0, total assets $3.46M, total liabilities $10.1M, shareholders' equity −$6.67M
- Sep 30, 2024: cash n/a, total assets $4.29M, total liabilities $10.5M, shareholders' equity −$6.19M
Is TVGNW profitable?
No. TEVOGEN BIO HLDGS INC lost $21.6M over the last four quarters.
What is TVGNW's EPS?
Diluted earnings per share over the last four quarters were −$6.25; −$1.52 in the latest quarter.